In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
The year in review: Updates and trends
In 2022, we witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues,...